SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
07 2021
Historique:
received: 18 06 2021
accepted: 27 06 2021
revised: 28 07 2021
pubmed: 17 7 2021
medline: 6 8 2021
entrez: 16 7 2021
Statut: epublish

Résumé

T-cell immunity is likely to play a role in protection against SARS-CoV-2 by helping generate neutralizing antibodies. We longitudinally studied CD4 T-cell responses to the M, N, and S structural proteins of SARS-CoV-2 in 26 convalescent individuals. Within the first two months following symptom onset, a majority of individuals (81%) mounted at least one CD4 T-cell response, and 48% of individuals mounted detectable SARS-CoV-2-specific circulating T follicular helper cells (cTfh, defined as CXCR5+PD1+ CD4 T cells). SARS-CoV-2-specific cTfh responses across all three protein specificities correlated with antibody neutralization with the strongest correlation observed for S protein-specific responses. When examined over time, cTfh responses, particularly to the M protein, increased in convalescence, and robust cTfh responses with magnitudes greater than 5% were detected at the second convalescent visit, a median of 38 days post-symptom onset. CD4 T-cell responses declined but persisted at low magnitudes three months and six months after symptom onset. These data deepen our understanding of antigen-specific cTfh responses in SARS-CoV-2 infection, suggesting that in addition to S protein, M and N protein-specific cTfh may also assist in the development of neutralizing antibodies and that cTfh response formation may be delayed in SARS-CoV-2 infection.

Identifiants

pubmed: 34270631
doi: 10.1371/journal.ppat.1009761
pii: PPATHOGENS-D-21-01273
pmc: PMC8318272
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Coronavirus Nucleocapsid Proteins 0
Phosphoproteins 0
Spike Glycoprotein, Coronavirus 0
Viral Matrix Proteins 0
membrane protein, SARS-CoV-2 0
nucleocapsid phosphoprotein, SARS-CoV-2 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1009761

Subventions

Organisme : NIAID NIH HHS
ID : F30 AI140829
Pays : United States
Organisme : NIAID NIH HHS
ID : F30 AI155295
Pays : United States

Commentaires et corrections

Type : UpdateOf

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Nat Med. 2020 Sep;26(9):1428-1434
pubmed: 32661393
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
J Immunol. 2016 Aug 1;197(3):983-93
pubmed: 27342848
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
JAMA Netw Open. 2020 May 1;3(5):e209759
pubmed: 32442288
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
Nat Commun. 2021 Feb 19;12(1):1162
pubmed: 33608522
Emerg Infect Dis. 2020 Aug;26(8):1834-1838
pubmed: 32383638
Nature. 2020 Sep;585(7824):174-177
pubmed: 32901123
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Clin Invest. 2018 Jul 2;128(7):3171-3185
pubmed: 29911996
Trends Immunol. 2014 Jun;35(6):278-86
pubmed: 24703588
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Vaccine. 2020 Feb 11;38(7):1778-1786
pubmed: 31911030
J Immunol. 2011 May 15;186(10):5556-68
pubmed: 21471443
Sci Transl Med. 2013 Mar 13;5(176):176ra32
pubmed: 23486778
J Exp Med. 2017 Jul 3;214(7):2139-2152
pubmed: 28637884
Immunity. 2013 Oct 17;39(4):758-69
pubmed: 24035365
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
J Virol. 2015 Dec 09;90(5):2208-20
pubmed: 26656715
J Immunol. 2015 Nov 15;195(10):4861-72
pubmed: 26466954
J Infect Dis. 2018 Oct 5;218(10):1675-1685
pubmed: 29917084
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Cell. 2020 Oct 1;183(1):143-157.e13
pubmed: 32877699
J Immunol Methods. 2003 Apr 1;275(1-2):19-29
pubmed: 12667667
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24384-24391
pubmed: 32913053
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
J Clin Invest. 2019 Jul 2;129(8):3185-3200
pubmed: 31264971
J Immunol Methods. 2001 Aug 1;254(1-2):59-66
pubmed: 11406153
PLoS Pathog. 2011 Jan 13;7(1):e1001251
pubmed: 21249232
Immunity. 2013 Oct 17;39(4):770-81
pubmed: 24138884
J Mol Biol. 2020 Sep 4;432(19):5212-5226
pubmed: 32710986
PLoS One. 2017 Oct 24;12(10):e0186998
pubmed: 29065175
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Nat Commun. 2020 Jul 8;11(1):3410
pubmed: 32641700
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Vaccines (Basel). 2020 May 27;8(2):
pubmed: 32471056
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
PLoS One. 2012;7(7):e40733
pubmed: 22792401
J Clin Invest. 2020 Dec 1;130(12):6588-6599
pubmed: 32841212
Cell Rep Med. 2020 Sep 22;1(6):100081
pubmed: 32839763
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 33119547
J Immunol Methods. 2007 May 31;323(1):39-54
pubmed: 17451739
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
J Virol. 2010 Feb;84(3):1289-301
pubmed: 19906920
Immunol Rev. 2010 Jul;236:110-24
pubmed: 20636812
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186

Auteurs

Sushma Boppana (S)

Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.

Kai Qin (K)

Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.

Jacob K Files (JK)

Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.

Ronnie M Russell (RM)

Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Department of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

Regina Stoltz (R)

Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

Frederic Bibollet-Ruche (F)

Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Department of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

Anju Bansal (A)

Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.

Nathan Erdmann (N)

Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.

Beatrice H Hahn (BH)

Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Department of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

Paul A Goepfert (PA)

Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH